Table 2.
Outcomes of the allopurinol group and comparisons on the use of diuretics
| No diuretics (n = 142 (68.3%)) |
Diuretics (n = 66 (31.7%)) |
P | |
|---|---|---|---|
| Primary outcome variable | |||
| Maximum dose of allopurinol (mg/day) | 304.9 (120.6) | 275.8 (119.7) | 0.109 |
| Secondary outcome variables | |||
| Baseline SU (mg/dL) | 8.1 (1.4) | 8.4 (1.6) | 0.116 |
| Final SU (mg/dL) | 4.9 (1.3) | 5.4 (1.7) | 0.015 |
| Final eGFR (mL/min) | 83.0 (24.4) | 64.6 (21.5) | < 0.001 |
| SU reduction (mg/dL) | 3.2 (1.8) | 3.0 (1.9) | 0.474 |
| Achievement of SU targets | |||
| - SU <6 mg/dL, n (%) | 110 (79.1) | 47 (68.1) | 0.082 |
| - SU <5 mg/dL, n (%) | 75 (54.0) | 27 (39.1) | 0.044 |
| - SU <4 mg/dL, n (%) | 34 (24.5) | 11 (15.9) | 0.160 |
Data shown as mean (SD) unless specified otherwise. In bold, statistically significant differences between subgroups. eGFR estimated glomerular filtration rate, SD standard deviation, SU serum urate